OSTEOARTHRITIS

ACS in Joint degeneration

Autologous blood derivatives are an evidence-based treatment option for osteoarthritis that has been proven over many years and recommended by leading professional societies.

Autologous conditioned serum rich in anti-inflammatory cytokines in Joint degeneration Still, current treatment approaches for osteoarthritis (OA) only help control the symptoms – to date there is no approved treatment to prevent or stop the progression of the disease. Despite the diversity of osteoarthritis, it is understood that controlling the chronic inflammatory response in the joint as early as possible may be an important component of treatment. It is assumed that various cytokines, such as IL-1 Ra or IL-10, have an inflammation-solving influence on certain aseptic inflammatory processes. [5]

This is where the autologous blood derivative “Autologous Conditioned Serum (ACS)” comes in. By following a specific ACS preparation protocol at the point-of-care, the release of anti-inflammatory cytokines is stimulated and the serum is also enriched with growth factors. [6] ACS is injected into the affected joints or, for example, also into mechanically compressed spinal roots, where it can exert a correspondingly positive effect. The body’s own beneficial proteins can have an inflammation-solving, pain-relieving and cartilage-protecting effect. [7]

Beyond classic OA in knee and hip, a positive effect of ACS has also been shown for egenerative spinal diseases (e.g. spondylarthrosis, osteochondrosis, spondylosis, degenerative spinal stenosis), nerve compression syndrome (e.g. intervertebral disc protrusion, intervertebral disc prolapse, degenerative neuroforaminal stenosis) and back pain.